PROFOUND MEDICAL CORP. Research and Development Expense
PROFOUND MEDICAL CORP. (PROF) reported Research and Development Expense of $5.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- PROFOUND MEDICAL CORP. research and development expense for the quarter ending 2026-06-30 was $5.65M, a 7.28% decline year-over-year.
- PROFOUND MEDICAL CORP. research and development expense for the quarter ending 2026-03-31 was $5.26M, a 9.44% increase year-over-year.
- PROFOUND MEDICAL CORP. research and development expense for the quarter ending 2025-12-31 was $4.27M, a 8.11% decline year-over-year.
- PROFOUND MEDICAL CORP. research and development expense for the quarter ending 2025-09-30 was $5.42M, a 30.05% increase year-over-year.
- PROFOUND MEDICAL CORP. research and development expense for fiscal 2025 was $20.60M, a 21.40% increase from fiscal 2024.
- PROFOUND MEDICAL CORP. research and development expense for fiscal 2024 was $16.96M, a 17.62% increase from fiscal 2023.
- PROFOUND MEDICAL CORP. research and development expense for fiscal 2023 was $14.42M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.65M 10-Q · filed 2026-08-06 | $10.92M 10-Q · filed 2026-08-06 | $15.19M derived: sum of 3 quarters · filed 2026-08-06 | $20.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.26M 10-Q · filed 2026-05-07 | $9.53M derived: sum of 2 quarters · filed 2026-05-07 | $14.95M derived: sum of 3 quarters · filed 2026-05-07 | $21.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $9.69M derived: sum of 2 quarters · filed 2026-03-05 | $15.79M derived: sum of 3 quarters · filed 2026-08-06 | $20.60M 10-K · filed 2026-03-05 |
| 2025-09-30 | $5.42M 10-Q · filed 2025-11-13 | $11.52M derived: sum of 2 quarters · filed 2026-08-06 | $16.32M 10-Q · filed 2025-11-13 | $20.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.10M 10-Q · filed 2026-08-06 | $10.91M 10-Q · filed 2026-08-06 | $15.55M derived: sum of 3 quarters · filed 2026-08-06 | $19.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.81M 10-Q · filed 2026-05-07 | $9.46M derived: sum of 2 quarters · filed 2026-05-07 | $13.62M derived: sum of 3 quarters · filed 2026-05-07 | $17.83M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $8.81M derived: sum of 2 quarters · filed 2026-03-05 | $13.02M derived: sum of 3 quarters · filed 2026-03-05 | $16.96M 10-K · filed 2026-03-05 |
| 2024-09-30 | $4.17M 10-Q · filed 2025-11-13 | $8.37M derived: sum of 2 quarters · filed 2025-11-13 | $12.32M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $4.21M 10-Q · filed 2025-08-14 | $8.15M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $3.94M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $14.42M 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |